|
DK2081929T3
(da)
|
2006-11-08 |
2013-04-15 |
Neurocrine Biosciences Inc |
Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
|
|
ES2652289T3
(es)
|
2008-09-18 |
2018-02-01 |
Auspex Pharmaceuticals, Inc. |
Derivados deuterados de benzoquinolina como inhibidores del transportador de monoamina vesicular 2
|
|
CN104744456A
(zh)
*
|
2010-06-01 |
2015-07-01 |
奥斯拜客斯制药有限公司 |
Vmat2的苯并喹啉酮抑制剂
|
|
WO2012000308A1
(zh)
*
|
2010-06-29 |
2012-01-05 |
中国药科大学 |
丁苯那嗪的拆分方法
|
|
US8351329B2
(en)
*
|
2010-09-14 |
2013-01-08 |
Cisco Technology, Inc. |
Universal load-balancing tunnel encapsulation
|
|
CN102285984B
(zh)
*
|
2010-11-25 |
2012-10-10 |
江苏威凯尔医药科技有限公司 |
(2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
|
|
WO2012081031A1
(en)
|
2010-12-15 |
2012-06-21 |
Enaltec Labs Pvt. Ltd. |
Process for preparing tetrabenazine
|
|
US9550780B2
(en)
|
2012-09-18 |
2017-01-24 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
CN116768882A
(zh)
|
2012-09-18 |
2023-09-19 |
奥斯拜客斯制药有限公司 |
化合物、及其药物组合物及治疗方法
|
|
EA201500801A1
(ru)
|
2013-01-31 |
2016-01-29 |
Ауспекс Фармацетикалс, Инк. |
Бензохинолоновые ингибиторы vmat2
|
|
US20160207917A1
(en)
*
|
2013-09-27 |
2016-07-21 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
MX369956B
(es)
|
2013-12-03 |
2019-11-27 |
Auspex Pharmaceuticals Inc |
Metodos para preparar compuestos de benzoquinolina.
|
|
KR20160111999A
(ko)
*
|
2014-01-27 |
2016-09-27 |
오스펙스 파마슈티칼스, 인코포레이티드 |
소포성 모노아민 수송체 2의 벤조퀴놀린 억제제
|
|
US10166183B2
(en)
|
2014-02-07 |
2019-01-01 |
Auspex Pharmaceuticals, Inc. |
Pharmaceutical formulations
|
|
RU2757221C2
(ru)
*
|
2014-02-07 |
2021-10-12 |
Ньюрокрайн Байосайенсиз, Инк. |
Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
|
|
SG10201806849WA
(en)
|
2014-02-13 |
2018-09-27 |
Incyte Corp |
Cyclopropylamines as lsd1 inhibitors
|
|
RS65359B1
(sr)
*
|
2014-05-06 |
2024-04-30 |
Neurocrine Biosciences Inc |
Režim doziranja valbenazina za lečenje poremećaja hiperkinetičkog kretanja
|
|
ES2960717T3
(es)
*
|
2015-02-06 |
2024-03-06 |
Neurocrine Biosciences Inc |
[9,10-Dimetoxi-3-(2-metilpropil)-1H,2H,3H,4H,6H,7H,11BH-pirido-[2,1-A]isoquinolin-2-il]metanol y compuestos, composiciones y métodos relacionados con el mismo
|
|
US20160287574A1
(en)
|
2015-03-06 |
2016-10-06 |
Auspex Pharmaceuticals, Inc. |
Methods for the treatment of abnormal involuntary movement disorders
|
|
US9944647B2
(en)
|
2015-04-03 |
2018-04-17 |
Incyte Corporation |
Heterocyclic compounds as LSD1 inhibitors
|
|
KR20180015260A
(ko)
*
|
2015-06-23 |
2018-02-12 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제
|
|
UA126277C2
(uk)
|
2015-08-12 |
2022-09-14 |
Інсайт Корпорейшн |
Солі інгібітору lsd1
|
|
BR112018007118A2
(pt)
|
2015-10-09 |
2018-12-11 |
Teva Pharmaceuticals Int Gmbh |
método para tratar um distúrbio de deficiência de dopamina, método para melhorar o tempo motor ativo sem discinesia num paciente com doença de parkinson, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir o tempo motor inativo num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir flutuações de nível de dopamina estriatal num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina após um tratamento de longo prazo, composição farmacêutica e embalagem
|
|
US10065952B2
(en)
*
|
2015-10-30 |
2018-09-04 |
Neurocrine Biosciences, Inc. |
Valbenazine salts and polymorphs thereof
|
|
LT3394057T
(lt)
|
2015-12-23 |
2022-06-27 |
Neurocrine Biosciences, Inc. |
Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
|
|
WO2017182916A1
(en)
*
|
2016-04-22 |
2017-10-26 |
Lupin Limited |
Novel process for preparation of tetrabenazine and deutetrabenazine
|
|
ES2811048T3
(es)
*
|
2016-06-29 |
2021-03-10 |
Crystal Pharmaceutical Suzhou Co Ltd |
Formas cristalinas de NBI-98854, método de preparación para las mismas y uso de las mismas
|
|
WO2018067945A1
(en)
|
2016-10-06 |
2018-04-12 |
Assia Chemical Industries Ltd. |
Solid state forms of valbenazine
|
|
TW202345829A
(zh)
|
2016-12-02 |
2023-12-01 |
美商紐羅克里生物科學有限公司 |
戊苯那嗪（valbenazine）於治療精神分裂症或情感性精神分裂症之用途
|
|
US10703750B2
(en)
|
2017-01-10 |
2020-07-07 |
Sandoz Ag |
Crystalline valbenazine free base
|
|
KR20190108146A
(ko)
|
2017-01-27 |
2019-09-23 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
JP2020508337A
(ja)
|
2017-02-27 |
2020-03-19 |
サンド・アクチエンゲゼルシヤフト |
バルベナジン塩の結晶形態
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
UA127052C2
(uk)
|
2017-03-15 |
2023-03-29 |
Оспекс Фармасьютікалс, Інк. |
Аналоги деутетрабеназину, їхнє отримання та застосування
|
|
GB201705303D0
(en)
*
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705305D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705306D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
AU2018241940B2
(en)
*
|
2017-04-01 |
2023-09-28 |
Adeptio Pharmaceuticals Limited |
Dihydrotetrabenazine for use in the treatment a movement disorder
|
|
GB201705304D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705302D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
JOP20190239A1
(ar)
*
|
2017-04-19 |
2019-10-09 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات منها
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
CN111372567B
(zh)
|
2017-09-21 |
2024-03-15 |
纽罗克里生物科学有限公司 |
高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
AU2017435893B2
(en)
*
|
2017-10-10 |
2023-06-29 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
EP3706748A4
(en)
*
|
2017-11-08 |
2021-08-11 |
Foresee Pharmaceuticals Co., Ltd. |
ESTER OF DIHYDROTETRABENAZINE
|
|
WO2019104141A1
(en)
|
2017-11-22 |
2019-05-31 |
Teva Pharmaceuticals Usa, Inc. |
Solid state form of valbenazine
|
|
JP7212958B2
(ja)
|
2017-12-26 |
2023-01-26 |
▲蘇▼州科睿思制▲葯▼有限公司 |
バルベナジントシル酸塩の結晶形及びその製造方法並びに用途
|
|
CN110092785A
(zh)
*
|
2018-01-31 |
2019-08-06 |
广东东阳光药业有限公司 |
一种丁苯那嗪的动态拆分方法
|
|
GB201808464D0
(en)
|
2018-05-23 |
2018-07-11 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compounds for use in treating huntington's disease
|
|
CA3100694A1
(en)
*
|
2018-06-14 |
2019-12-19 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
|
SG11202100303QA
(en)
|
2018-08-15 |
2021-02-25 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
US10968200B2
(en)
|
2018-08-31 |
2021-04-06 |
Incyte Corporation |
Salts of an LSD1 inhibitor and processes for preparing the same
|
|
WO2020070236A1
(en)
|
2018-10-04 |
2020-04-09 |
Adeptio Pharmaceuticals Limited |
(+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
|
|
CA3065236A1
(en)
|
2018-12-27 |
2020-06-27 |
Apotex Inc. |
Novel crystalline form of valbenazine dibesylate
|
|
WO2020213014A1
(en)
|
2019-04-19 |
2020-10-22 |
Mylan Laboratories Limited |
An improved process for the preparation of valbenazine and its salts
|
|
US10689380B1
(en)
|
2019-07-30 |
2020-06-23 |
Farmhispania S.A. |
Crystalline forms of valbenazine ditosylate
|
|
BR112022002107A2
(pt)
*
|
2019-08-12 |
2022-04-12 |
Shandong luye pharmaceutical co ltd |
Inibidor de vmat2 e método de preparação para o mesmo e aplicação do mesmo
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
CA3150961A1
(en)
|
2019-09-13 |
2021-03-18 |
John Tucker |
Processes for the synthesis of valbenazine
|
|
CN110698397A
(zh)
*
|
2019-10-28 |
2020-01-17 |
南京红杉生物科技有限公司 |
丁苯那嗪中间体及其合成方法、应用和合成用中间产物
|
|
MD4168409T2
(ro)
|
2021-03-22 |
2025-09-30 |
Neurocrine Biosciences Inc |
Inhibitori VMAT2 și metode de utilizare
|
|
WO2022232060A1
(en)
|
2021-04-26 |
2022-11-03 |
Neurocrine Biosciences, Inc. |
Processes for the synthesis of valbenazine
|
|
IL309171A
(en)
|
2021-06-30 |
2024-02-01 |
Neurocrine Biosciences Inc |
Vulbanazine for use in the treatment of dyskinesia due to cerebral palsy
|
|
IL309172A
(en)
|
2021-06-30 |
2024-02-01 |
Neurocrine Biosciences Inc |
Vulbanazine for use in the additional treatment of schizophrenia
|
|
AU2023232134A1
(en)
|
2022-03-07 |
2024-10-03 |
Neurocrine Biosciences, Inc. |
Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
|
|
CN119907800A
(zh)
|
2022-09-21 |
2025-04-29 |
纽罗克里生物科学有限公司 |
六氢-2H-吡啶并[2,1-a]异喹啉VMAT2抑制剂及其使用方法
|
|
WO2025038959A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025038938A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Valbenazine for use in the treatment of huntington's chorea
|
|
WO2025096823A1
(en)
|
2023-11-01 |
2025-05-08 |
Neurocrine Biosciences, Inc. |
Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
|
|
WO2025188830A1
(en)
|
2024-03-06 |
2025-09-12 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025199234A1
(en)
|
2024-03-20 |
2025-09-25 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors and methods of use
|